Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 24.20 TWD
Change Today -0.30 / -1.22%
Volume 138.3K
4172 On Other Exchanges
As of 2:32 AM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

innopharmax inc (4172) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/14 - 63.00
52 Week Low
08/24/15 - 18.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INNOPHARMAX INC (4172)

Related News

No related news articles were found.

innopharmax inc (4172) Related Businessweek News

No Related Businessweek News Found

innopharmax inc (4172) Details

INNOPHARMAX, Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and specialty in Taiwan. Its products include anti-infection agents, such as Bestnem, an imipenem and cilastatin sodium solution that is used intravenous in the treatment of serious infections caused by susceptible organisms, including lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, or bone and joint infections; gadopentetate dimeglumine, a contrast medium for magnetic resonance imaging (MRI) of the body after intravenous administration; and gadodiamide, a contrast medium for cranial and spinal MRI, as well as for general MRI of the body after intravenous administration. The company’s products also comprise oncology agents, such as Innomustine; and immunological agents, including Cyclosporine A, an immuno-suppresant with a low aqueous solubility used for the inhibition of graft rejection in organ transplant recipients. Its products pipeline includes CNS agents, urology agents, oncology agents, cardiovascular agents, immunological agents, and contrast agents, as well as agents for metabolic disorders. The company also undertakes contract formulation development of pharmaceuticals ranging from immediate release formulations to alternative dosage designs and controlled release formulations, based on the company’s technology platform and advanced equipment. INNOPHARMAX, Inc. was founded in 2005 and is based in Taipei City, Taiwan.

Founded in 2005

innopharmax inc (4172) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

innopharmax inc (4172) Key Developments

INNOPHARMAX, Inc., Annual General Meeting, Jun 15, 2015

INNOPHARMAX, Inc., Annual General Meeting, Jun 15, 2015.

INNOPHARMAX, Inc., Annual General Meeting, Jun 19, 2014

INNOPHARMAX, Inc., Annual General Meeting, Jun 19, 2014.

InnoPharma Inc. Completes $20 Million Term Loan Facility

InnoPharma, Inc. announced that it has closed on a $20 million term loan facility, provided by Athyrium Capital Management through its Athyrium Opportunities Fund. Proceeds will support the company's ongoing development of complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. Armentum Partners acted as financial advisors to InnoPharma for this transaction.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4172:TT 24.20 TWD -0.30

4172 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4172.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4172 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.2x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOPHARMAX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at